The SFDA has signed an agreement with the Uppsala Monitoring Centre (UMC), Sweden, to link Saudi Arabia’s national pharmacovigilance database with the WHO global safety database for adverse drug reaction reporting.

Key Highlights:

  • Agreement formalized during the visit of Mr. Fahd bin Abdulrahman Al-Jalajel, Minister of Health and Chairman of the SFDA Board
  • Enhances early detection of adverse drug reactions and improves Regulatory decision-making
  • Strengthens the Kingdom’s pharmacovigilance system and aligns it with international standards
  • Demonstrates Saudi Arabia’s commitment to global drug safety collaboration
  • Reinforces the Kingdom’s position as a reliable international partner in advancing global Regulatory practices

Consult Now

Source
https://www.sfda.gov.sa/ar/news/5124593
Select Mandate HA
SFDA
Select Mandate Function
Regulatory Affairs